Abstract:The long-term physiological consequences of SARS-CoV-2, termed Post-Acute Sequelae of COVID-19 (PASC), are rapidly evolving into a major public health concern. The underlying cellular and molecular etiology remain poorly defined but growing evidence links PASC to abnormal immune responses and/or poor organ recovery post-infection. Yet, the precise mechanisms driving non-resolving inflammation and impaired tissue repair in the context of PASC remain unclear. With insights from three independent clinical cohorts of PASC patients with abnormal lung function and/or viral infection-mediated pulmonary fibrosis, we established a clinically relevant mouse model of post-viral lung sequelae to investigate the pathophysiology of respiratory PASC. By employing a combination of spatial transcriptomics and imaging, we identified dysregulated proximal interactions between immune cells and epithelial progenitors unique to the fibroproliferation in respiratory PASC but not acute COVID-19 or idiopathic pulmonary fibrosis (IPF). Specifically, we found a central role for lung-resident CD8+ T cell-macrophage interactions in maintaining Krt8hi transitional and ectopic Krt5+ basal cell progenitors, thus impairing alveolar regeneration and driving fibrotic sequelae after acute viral pneumonia. Mechanistically, CD8+ T cell derived IFN-γ and TNF stimulated lung macrophages to chronically release IL-1β, resulting in the abnormal accumulation of dysplastic epithelial progenitors and fibrosis. Notably, therapeutic neutralization of IFN-γ and TNF, or IL-1β after the resolution of acute infection resulted in markedly improved alveolar regeneration and restoration of pulmonary function. Together, our findings implicate a dysregulated immune-epithelial progenitor niche in driving respiratory PASC. Moreover, in contrast to other approaches requiring early intervention, we highlight therapeutic strategies to rescue fibrotic disease in the aftermath of respiratory viral infections, addressing the current unmet need in the clinical management of PASC and post-viral disease.

Postinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop Report

Pathogenesis of Post-Tuberculosis Lung Disease: Defining Knowledge Gaps and Research Priorities at the 2nd International Post-Tuberculosis Symposium

The past decade in bench research into pulmonary infectious diseases: What do clinicians need to know?

An aberrant immune-epithelial progenitor niche drives viral lung sequelae

Proximal immune-epithelial progenitor interactions drive chronic tissue sequelae post COVID-19

The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease

D-PRISM, a global study of diagnostic approaches in severe pneumonia.

Long COVID and post‐acute sequelae of SARS‐CoV‐2 pathogenesis and treatment: A Keystone Symposia report

Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group

Infection and pulmonary vascular diseases consortium: United against a global health challenge

Trends in the Epidemiology of Pneumocystis Pneumonia in Immunocompromised Patients without HIV Infection

Respiratory follow-up of patients with COVID-19 pneumonia

Research progress of post-acute sequelae after SARS-CoV-2 infection

Pathophysiology of Pulmonary Fibrosis in the Context of COVID-19 and Implications for Treatment: A Narrative Review

Post-Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global Challenge

Paediatric pneumonia research priorities in the context of COVID-19: An eDelphi study

Paediatric pneumonia research priorities in the context of COVID-19: A eDelphi study

Chronic Lung Injury after COVID-19 Pneumonia: Clinical, Radiologic, and Histopathologic Perspectives

Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission

The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness

Focusing on the long-term recovery of severe acute respiratory syndrome coronavirus 2 infection: Clinically relevant observations